Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Core Insights - Cadrenal Therapeutics is advancing CAD-1005 as a lead development priority for treating heparin-induced thrombocytopenia (HIT), supported by encouraging Phase 2 data and recent FDA feedback [1][3] - The company is also exploring broader opportunities within its 12-LOX inhibitor platform for future value creation [1][3] Recent Highlights - CAD-1005 demonstrated a greater than 25% absolute reduction in thrombotic events compared to placebo in a Phase 2 study, indicating its potential as a differentiated treatment for HIT [7] - The End-of-Phase 2 meeting with the FDA clarified the regulatory path for CAD-1005, with the company currently incorporating FDA feedback into the Phase 3 trial protocol [7][3] Financial Performance - For Q4 2025, research and development expenses were $0.7 million, down from $1.5 million in Q4 2024, while general and administrative expenses decreased to $2.4 million from $2.7 million [4] - The net loss for Q4 2025 was $3.0 million, an improvement from a net loss of $4.2 million in the same quarter of 2024 [4] Cash Position - As of December 31, 2025, Cadrenal had cash and cash equivalents of $4.0 million, down from $10.0 million in 2024, and is evaluating financing options to support clinical development activities [5][12] Company Overview - Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on novel therapies for life-threatening immune and thrombotic conditions, with CAD-1005 being its first-in-class 12-LOX inhibitor [8] - The company also has a broader pipeline that includes tecarfarin and frunexian, targeting chronic anticoagulation and acute hospital settings, respectively [9]